Categories
SauveBio
About CRO
SauveBio is a premier Contract Research Organization (CRO) specializing in advanced flow cytometry and cell sorting services, dedicated to accelerating scientific discovery in biotechnology and pharmaceutical research. Founded by Hannah Sheehan, Ph.D., and Jeff Sauve, we combine cutting-edge technology with unparalleled expertise to deliver precise, reliable data for drug development and biological research. Located in Worcester, MA, we serve as an extension of your research team, offering personalized collaboration, customized experimental design, and rapid turnaround times.
Technology & Expertise
We leverage state-of-the-art instrumentation, including the BD FACSymphony S6 cell sorter, to provide high-dimensional single-cell analysis and nanoscale flow cytometry. Our team of Ph.D.-level scientists, led by Dr. Hannah Sheehan, brings extensive experience in flow cytometry, with expertise honed at institutions like Northeastern University and AbbVie. Our in-house cell line repository and robust Quality Management System ensure reproducible, high-quality results for preclinical and translational studies.
Core Services
High-Parameter Immunophenotyping: Comprehensive analysis of immune cell populations using advanced flow cytometry techniques. Fluorescence-Activated Mitochondria Sorting (FAMS): Innovative nanoscale sorting for mitochondrial analysis. Nuclei Isolation: Flow cytometry-based solutions to generate quality samples for single-nucleus RNA sequencing (snRNA-seq) studies. Exosome Characterization and Isolation: Specialized assays for studying extracellular vesicles. Receptor Occupancy Studies: Quantification of therapeutic molecule binding to target receptors. Custom Assay Development: Tailored flow cytometry panels and experimental designs to meet specific research needs. Data Analysis with FlowJo: Expert analysis and interpretation using industry-standard software.
Accreditations & Compliance
SauveBio follows rigorous quality control, sample traceability, and data security protocols to ensure scientific and regulatory readiness across preclinical studies.
